Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

PRACINOSTAT

Inhibitor of class I, II, and IV HDAC

ONCOLOGY

CURRENT DEVELOPMENT PHASE: acute myeloid leukaemia and myelodysplastic syndrome

preclinicl
phase i
phase ii
phase iii
pre-registration
post-registration

PRACINOSTAT (MDS)


PRACINOSTAT (AML)

In December 2018, the Menarini Group signed with Helsinn an exclusive licensing agreement to commercialize Pracinostat worldwide (excluding US, Canada, Japan and South America).

Pracinostat is an inhibitor of class I, II, and IV histone deacetylase in clinical development.

The compound is currently in development with a multiregional phase III trial in combination with Azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive induction chemotherapy.

Pracinostat is also being tested in an open label phase II study in combination with Azacitidine for the treatment of naïve patients with high risk myelodysplastic syndrome (MDS).

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for Pracinostat in combination with Azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy.

VISIT OUR CLINICAL TRIALS DATABASE

THERAPEUTIC AREAS

Discover all of Menarini's products marketed in Italy. Read More »

DIAGNOSTICS

 

Advanced Technology

READ MORE »

THE MENARINI GROUP

Discover the leading Italian pharmaceutical company in the world. Read More »

MENARINI PILLS OF ART

Concession granted by Italian Ministry for Cultural Heritage and Activities Read more